Emmaus Life Sciences Announces Informational Stockholders Meeting
September 01, 2020 08:00 ET
|
Emmaus Life Sciences
TORRANCE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today that it will hold an informational meeting...
UPDATE - Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority
August 18, 2020 13:41 ET
|
Emmaus Life Sciences
TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi...
Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority
August 18, 2020 08:00 ET
|
Emmaus Life Sciences
TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi...
エマウスライフサイエンス社、憩室症パイロット試験における肯定的な中間結果を追加報告
August 06, 2020 19:00 ET
|
Emmaus Life Sciences
--憩室数の減少およびより健康な組織を示す中間分析-- カリフォルニア州トーランス市, Aug. 07, 2020 (GLOBE NEWSWIRE) -- 鎌状赤血球症治療をリードするエマウスライフサイエンス社(OTCPK:...
엠마우스생명과학 게실증 시범임상 연구 긍정적인 추가 예비결과
August 05, 2020 19:00 ET
|
Emmaus Life Sciences
캘리포니아주 토랜스, Aug. 06, 2020 (GLOBE NEWSWIRE) -- 겸상상적혈구질환 치료의 선두주자 엠마우스생명과학(“엠마우스”, OTCPK: EMMA)은 게실증 시범임상연구에서 예정된 12개월 치료기간 중, 최근 6개월 치료기간이 완료된 2명의 환자에 대한 탑라인 중간 데이터를 발표하였다. 시범임상 탑라인 중간결과가 지난 1월 29일...
Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot Trial
August 05, 2020 08:00 ET
|
Emmaus Life Sciences
--Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue-- TORRANCE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle...
Emmaus Life Sciences Provides Additional Operational and OTC Markets Updates
July 31, 2020 08:00 ET
|
Emmaus Life Sciences
TORRANCE, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today additional operational updates for the year...
Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari™
July 29, 2020 12:09 ET
|
Emmaus Life Sciences
TORRANCE Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EMA)...
Emmaus Life Sciences Accelerates Middle East and North Africa (MENA) Growth Strategy with Opening of its Dubai Office
July 23, 2020 13:14 ET
|
Emmaus Life Sciences
TORRANCE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the opening of its regional office in Dubai....
エマウスライフサイエンス社がEndariを用いた憩室症治療のライセンス供与についてパートナー・インターナショナル社との契約を発表
July 16, 2020 19:00 ET
|
Emmaus Life Sciences
カリフォルニア州トーランス市, July 17, 2020 (GLOBE NEWSWIRE) -- 鎌状赤血球症治療をリードするエマウスライフサイエンス社(OTCQB:...